ClinicalTrials.gg
RecruitingNCT07745504RENEW 4Updated Sep 4, 2026

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

A Phase 3 interventional study of Cagrilintide and Placebo cagrilintide in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 36 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
16th of 36
285 · median 154
Started
2026
with 9 others
Phase 3
15 of 36
4 open now
Primary completion
2027-05
later than 3 of 14 live
Registered
35th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 16th largest by planned enrollment, is one of 10 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 3 of the 14 other live ones, and was the 35th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's planned enrollment of 285 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 years or above at the time of signing the informed consent.
  • (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m\^2), or BMI >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion criteria

Exclusion criteria:

  • History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
  • Previous dosing of marketed or non-marketed amylin-based compounds.
  • Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2

    Participants will receive cagrilintide along with placebo matched to semaglutide in device 1 and placebo matched to cagrilintide in device 2 subcutaneously (s.c) once weekly for 26 weeks.

    Drug: Cagrilintide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide

  • Experimental
    Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1

    Participants will receive cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.

    Drug: Cagrilintide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide

  • Placebo comparator
    Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1

    Participants will receive placebo matched to cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Cagrilintide will be administered subcutaneously.

  • DrugPlacebo cagrilintide

    Placebo matched to cagrilintide will be administered subcutaneously.

  • DrugPlacebo semaglutide

    Placebo matched to semaglutide will be administered subcutaneously.

07

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured as percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 26)

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 33)

  2. Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 33)

08

Study locations

35 of 36 sites recruiting
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
    Recruiting
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
    Recruiting
  • Walgreens - Store 11760
    Oak Park, Illinois 60302, United States
    Not yet recruiting
  • Midwest Inst For Clin Res
    Indianapolis, Indiana 46260, United States
    Recruiting
  • The Alliance for Multispecialty Research LLC AMR
    Lexington, Kentucky 40509, United States
    Recruiting
  • PharmQuest
    Greensboro, North Carolina 27408, United States
    Recruiting
  • KDCILM, LLC & Accellacare US, Inc.
    Wilmington, North Carolina 28401, United States
    Recruiting
  • Coastal Carolina Res Ctr
    North Charleston, South Carolina 29405, United States
    Recruiting
  • Health Res of Hampton Roads
    Newport News, Virginia 23606, United States
    Recruiting
  • National Clin Res Inc.
    Richmond, Virginia 23294, United States
    Recruiting
  • Selma Medical Associates
    Winchester, Virginia 22601-3834, United States
    Recruiting
  • General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center
    Athens, 115 28, Greece
    Recruiting
  • General Hospital Of Athens G Gennimatas - Department of Endocrinology
    Athens, 11527, Greece
    Recruiting
  • General Hospital Venizeleio-Pananeio - Diabetic Clinic
    Irakleio, 71409, Greece
    Recruiting
  • Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department
    Peristeri, 121 31, Greece
    Recruiting
  • Ippokratio General Hospital Of Thessaloniki - B' Internal Medicine clinic
    Thessaloniki, 546 42, Greece
    Recruiting
  • St. Luke's Hospital S.A. - Endocrinology Department and Obesity Clinic
    Thessaloniki, 552 36, Greece
    Recruiting
  • Stúdium Egészségház Kft.
    Kalocsa, Bács-Kiskun county 6300, Hungary
    Recruiting
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
    Recruiting
  • Trial Pharma Kft.
    Kecskemét, 6000, Hungary
    Recruiting
  • KomplexLabor Diagnosztika Kft.
    Szeged, 6724, Hungary
    Recruiting
  • ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes
    Caldas da Rainha, 2500-176, Portugal
    Recruiting
  • ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cirurgia (Esp. Endocrinologia)
    Figueira da Foz Municipality, 3094-001, Portugal
    Recruiting
  • Hospital São Francisco, S.A_EECC
    Leiria, 2400-110, Portugal
    Recruiting
  • APDP - Associação Protectora dos Diabéticos de Portugal
    Lisbon, 1250-189, Portugal
    Recruiting
  • CVP Hospital Cruz Vermelha_Cardiologia
    Lisbon, 1549-008, Portugal
    Recruiting
  • ULS De Gaia/Espinho_H.Santos Silva_Endocrinologia
    Vila Nova de Gaia, 4434-502, Portugal
    Recruiting
  • Endocrinology, Diabetes and Metabolism Diseases Clinic
    Belgrade, 11000, Serbia
    Recruiting
  • Institute for Cardiovascular Diseases of Vojvodina - Sremska Kamenica
    Kamenitz, 21204, Serbia
    Recruiting
  • Clinical Centre Nis, Endocrinology, Diabetes and Metabolism
    Niš, 18000, Serbia
    Recruiting
  • University Clinical Centre Nis, Clinic for Cardiology
    Niš, 18108, Serbia
    Recruiting
  • Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
    Novi Sad, 21000, Serbia
    Recruiting
  • Skånes Universitets Sjukhus
    Lund, 222 42, Sweden
    Recruiting
  • Forsåker vårdcentral
    Mölndal, 431 33, Sweden
    Recruiting
  • Örebro US - Överviktsenheten
    Örebro, 701 85, Sweden
    Recruiting
  • Dalecarlia Clinical Research AB
    Rättvik, 795 30, Sweden
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2027, 9 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 9 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartActual
Aug 4, 2026
Primary completionEst.
May 18, 2027
CompletionEst.
Jul 6, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07745504
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Aug 4, 2026
Primary completion
May 18, 2027 (estimated)
Completion
Jul 6, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion